

Escitalopram, HRP conjugate

DAG1159

Lot. No. (See product label)

PRODUCT INFORMATION

Product overview Escitalopram, HRP conjugate

Antigen Description Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is

approved by the U.S. Food and Drug Administration (FDA) for the treatment in adults with major depressive disorder, generalized anxiety disorder, social anxiety disorder, or panic disorder. Escitalopram is the S-stereoisomer (enantiomer) of the earlier Lundbeck drug citalopram, hence the name Escitalopram. Escitalopram is noted for its high selectivity of serotonin reuptake inhibition and

has side effects typical for the SSRI class.

Source Antidepressants

Conjugate HRP

Form concentrate

Characteristic Each conjugate comprises antigen covalently bound to horseradish peroxide and is suitable as a

tracer in immunoassay development

PACKAGING

Storage Can be stored at 2-8°C for up to 3 months and at -20°C for longer term storage.

BACKGROUND

Introduction Escitalopram is the (S)-stereoisomer (enantiomer) of the earlier Lundbeck drug citalopram, hence the

name escitalopram. Escitalopram is noted for its high selectivity with serotonin reuptake inhibition. Its side effects are typical for the SSRI class. Only one independent study has shown that escitalopram is more effective than citalopram, but in October 2011 it was reported that the company that sponsored the study had links to Lundbeck, the makers. The similarity between escitalopram and citalopram has

led to accusations of "evergreening", an accusation that Lundbeck has rejected.

Keywords Escitalopram; Nexito; Anxiset-E; Lexapro; Cipralex; Seroplex; Lexamil; Lexam; Entact; Losita; Reposil;

(S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile

REFERENCES

1. Cipriani, A; Santilli C; Furukawa TA; Signoretti A; Nakagawa A; McGuire H; Churchill R; Barbui C (2009 April 15). Cipriani, Andrea. ed. "Escitalopram versus other antidepressant agents for depression". Cochrane database of systematic reviews (2): CD006532. DOI:10.1002/14651858.CD006532.pub2. PMID 19370639. CD006532. 2. Cipriani, A; Furukawa TA; Salanti G; Geddes JR; Higgins JP; Churchill R; Watanabe N; Nakagawa A; Omori IM; McGuire H; Tansella M; Barbui C (2009 February 28). "Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis". Lancet 373 (9665): 746–58. DOI:10.1016/S0140-6736(09)60046-5. PMID 19185342.